GENFIT
Develops therapies and diagnostics for patients with rare and severe liver diseases.
GNFT | PA
Overview
Corporate Details
- ISIN(s):
- FR0004163111 (+2 more)
- LEI:
- 969500XPWN2DMZQA5X73
- Country:
- France
- Address:
- 885 AVENUE EUGENE AVINEE, 59120 LOOS
- Website:
- https://www.genfit.com
Description
GENFIT is a biopharmaceutical company dedicated to developing therapeutic and diagnostic solutions for patients with rare and severe liver diseases characterized by high unmet medical needs. The company's primary focus is on Acute-on-Chronic Liver Failure (ACLF) and its associated conditions, such as acute decompensation (AD) and hepatic encephalopathy (HE). Leveraging a scientific heritage of over two decades, GENFIT is a pioneer in liver disease research and development, aiming to improve the lives of patients with these life-threatening conditions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2019-07-29 08:19 |
GENFIT: FDA and EMA Grant GENFIT’s Elafibranor Orphan Drug Designation for Prim…
|
English | 183.6 KB | ||
| 2019-07-29 08:19 |
GENFIT : La FDA et l’EMA accordent la désignation d’Orphan Drug à elafibranor p…
|
French | 191.1 KB | ||
| 2019-07-09 07:30 |
GENFIT: Half-Year report of Liquidity Contract with Crédit Industriel et Commer…
|
English | 167.3 KB | ||
| 2019-07-09 07:30 |
GENFIT : Bilan semestriel du contrat de liquidité contracté avec le Crédit Indu…
|
French | 168.2 KB | ||
| 2019-06-24 22:10 |
GENFIT : GENFIT et Terns Pharmaceuticals annoncent un partenariat stratégique d…
|
French | 347.5 KB | ||
| 2019-06-13 22:40 |
GENFIT: Outcome of the Ordinary Shareholder’s Meeting of June 13, 2019
|
English | 282.1 KB | ||
| 2019-06-13 22:40 |
GENFIT : Résultats de l’assemblée générale ordinaire du 13 juin 2019
|
French | 287.8 KB | ||
| 2019-06-12 08:20 |
GENFIT: GENFIT annonce sa participation active à la 2e Journée Internationale d…
|
French | 431.5 KB | ||
| 2019-06-12 08:20 |
Genfit: GENFIT Announces Active Participation in the 2nd Annual International N…
|
English | 461.4 KB | ||
| 2019-06-04 22:19 |
Genfit: GENFIT lance un essai de Phase 2 évaluant l’effet d’elafibranor sur la …
|
French | 288.0 KB | ||
| 2019-06-04 22:19 |
Genfit: GENFIT Launches a Phase 2 Trial Evaluating Elafibranor on Hepatic Lipid…
|
English | 208.3 KB | ||
| 2019-05-23 22:05 |
Genfit: GENFIT Launches a Combination Therapy Clinical Program in NASH
|
English | 199.2 KB | ||
| 2019-05-14 08:05 |
GENFIT : Issue positive du DSMB à 36 mois, recommandant la poursuite de l’étude…
|
French | 214.3 KB | ||
| 2019-05-14 08:05 |
GENFIT: Positive 36-month DSMB Recommendation for Continuation of Phase 3 RESOL…
|
English | 508.4 KB | ||
| 2019-05-10 08:05 |
GENFIT: Ordinary Shareholder’s Meeting of June 13, 2019 – Availability of Prepa…
|
English | 364.5 KB |
Automate Your Workflow. Get a real-time feed of all GENFIT filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for GENFIT
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for GENFIT via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-07-07 | N/A | Other | Buy | 5,300 | 19,488.10 EUR |
| 2023-07-06 | N/A | Other | Buy | 1,100 | 4,048.00 EUR |
| 2023-07-05 | N/A | Other | Buy | 10,000 | 37,061.00 EUR |
| 2023-07-03 | N/A | Other | Buy | 5,300 | 18,769.95 EUR |
Peer Companies
